Product nameAnti-CD45 antibody [IBL-3/16]
See all CD45 primary antibodies
DescriptionRat monoclonal [IBL-3/16] to CD45
Tested applicationsSuitable for: IP, ICC/IF, Flow Cyt, IHC-Frmore details
Unsuitable for: IHC-P,IHC-R or WB
Species reactivityReacts with: Mouse
Does not react with: Rat, Human
Purified B cells from mouse lymph nodes.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term.
Storage bufferpH: 7.20
Preservative: 0.09% Sodium azide
Constituents: PBS, 0.1% BSA
Concentration information loading...
Purification notesIg fraction prepared by ammonium sulphate precipitation from tissue culture supernatant.
Our Abpromise guarantee covers the use of ab23910 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IP||Use at an assay dependent concentration.|
|ICC/IF||Use at an assay dependent concentration.|
Use 50µl of the suggested working dilution to label 105 cells in 100µl.
ab18407 - Rat monoclonal IgG1, is suitable for use as an isotype control with this antibody.
FunctionProtein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN.
Involvement in diseaseDefects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain.
Sequence similaritiesBelongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
Contains 2 fibronectin type-III domains.
Contains 2 tyrosine-protein phosphatase domains.
DomainThe first PTPase domain interacts with SKAP1.
modificationsHeavily N- and O-glycosylated.
Cellular localizationMembrane. Membrane raft. Colocalized with DPP4 in membrane rafts.
- Information by UniProt
- B220 antibody
- CD 45 antibody
- CD45 antibody
ab23910 staining the CD45 in Mouse brain tissue sections by IHC-Fr (frozen sections). Tissue was fixed with acetone and blocked with 5% BSA for 10 hours at 20°C. Samples were incubated with primary antibody (1/100) for 1 hour at 20°C. An Alexa Fluor®-conjugated goat anti-rat IgG polyclonal (1/300) was used as the secondary antibody.
This product has been referenced in:
- Raso A et al. Therapeutic Delivery of miR-148a Suppresses Ventricular Dilation in Heart Failure. Mol Ther 27:584-599 (2019). Read more (PubMed: 30559069) »
- Wang F et al. Data on the expression and role of TREM-1 in the development of in-stent restenosis. Data Brief 16:604-607 (2018). Read more (PubMed: 29264376) »